Latest news, reports, and more from the RedChip Nation!
Can't see this Email? View it in your Browser
RedChip.com     Stocks     Contact    
 
REDCHIP MONEY REPORT
 
Mar 23, 2016
 
 
New Report on Revenue Generating Biotech, with EU and U.S. Approval Expected by 2017; Price Target $6.87
 
RedChip just issued a new research report on Oasmia Pharmaceutical AB (NASDAQ: OASM) with a price target of $6.87 per share.

OASM develops new cancer drugs for use in humans and animals. The Company’s technology is a drug-delivery system that, in comparison with current alternatives, improves care, reduces side-effects, and reduces patient treatment times. OASM’s lead drug Paclical is a chemotherapy drug that demonstrates equal efficacy to chemotherapy drugs Taxol and Abraxane while providing a superior risk profile. Paclical, which has completed a successful phase 3 clinical trial, has been launched in Russia and is expected to receive European approval in 2H16 and U.S. approval in 2017.

All of OASM’s therapies that are currently in clinical trials are based on APIs that make up approximately 80% of chemotherapy usage. These chemotherapies generate significant sums of annual revenue across a variety of different types of cancers. We believe that the Company’s therapies (Paclical, Docecal, and Doxophos) could eventually gain approval for some of these indications. This gives the Company’s XR-17 technology long-term platform potential. RedChip Director of Research, Thomas Pfister, a Chartered Financial Analyst, has given OASM a price target of $6.87 per share. With the stock trading at around $3 today, this represents a compelling upside for investors. Learn more about OASM by reading the full report.

 
 
Read Report Now
 
 
 
 
 
RedChip Top Performers 2015-2016
 
Learn More
 
 
 
 
 
Global Online Growth Conference
 
 
 
RedChip Global Online Growth Conference
 
More than a dozen leading microcap and small-cap stocks presented at our online conference in February. Watch the replays, including Q&A sessions with management, today.
 
 
Watch Replays
 
 
 
 
Quote of the Week
 
"Small caps outperform not because of market capitalization alone but because the stocks in this category are least efficiently priced."
-James O’Shaughnessy, Author of What Works on Wall Street
 
 
 
 
 
Lesson of the Week
 
Tracking insider buying is a way to find situations that warrant attention.
Read More
 
 
 
 
 
This Week on RedChip TV
 
This Week on RedChip TV: Interviews with PharmAust & Prescient Therapeutics.
Watch the full episode now.
 
 
 
 
Latest Videos & Interviews
 
 
 
 
 
American Caresource Holdings, Inc: Publicly Traded Urgent Care Consolidator
 
Watch Now
 
 
 
 
Imugene: Phase II Ready Drug Targeting Gastric Cancer
 
Watch Now
 
 
 
 
Calpian: Leading Mobile Money Solution in India
 
Watch Now
 
 
 
 
Provision: Rolling Out Innovative 3D Ad Display Technology
 
Watch Now
 
 
 
 
Order "Small Stocks, Big Money" Today!
 
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
 
 
 
Latest News from the RedChip Nation
 
Read the latest news from ESES, BTCS, CLPI and more. Read More
 
 
 
MidSouth Week in Review
 
Buzz thinks the stock market is overbought and it’s time for a reversion to the mean.
Read More
 
 
Recent Reports
 
 
 
 
 
Top Movers of the Week
 
SAKL, PVHO, CGIX and other Nation stocks posted 20%+ gains last week.
 
 
Weekly Index Performance
 
After several volatile sessions, the markets finished the week with moderate gains.
 
 
Insider Buying Report
 
No major changes to insider buying last week.
 
 
Bear Market Facts
 
Four important facts about bear markets.
 
 
Book Review
 
Dave Gentry reviews "Lords of Finance", a bestseller that explores the role of central bankers in the crash of 1929.
 
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. For 23 years, RedChip has delivered concrete, measurable results for its clients. Our digital magazine, the RedChip Money Report is delivered on-line weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include the following: a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually, a globally-televised show, "The RedChip Money Report,” which airs weekly in 200 million homes in Europe, Asia, Latin America, and Australia on the Bloomberg network and in the U.S. on Newmax TV (available on DIRECTV and Dish Network); TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.